Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care
January 15, 2025 08:05 ET
|
Amwell
Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care.
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
January 13, 2025 09:00 ET
|
Biomea Fusion, Inc.
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...
Beta Bionics Files Registration Statement for Proposed Initial Public Offering
January 06, 2025 17:14 ET
|
Beta Bionics, Inc.
Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC.
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 07:00 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
CORXEL Acquires Worldwide (excluding Greater China) Rights to an Oral Small Molecule GLP-1 RA for the Treatment of Obesity and Diabetes
December 23, 2024 08:01 ET
|
Corxel Pharmaceuticals
CORXEL expands its cardiometabolic pipeline into obesity and diabetes.
Hypophosphatasia Epidemiology Forecast Report 2034: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
December 18, 2024 09:58 ET
|
Research and Markets
Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Hypophosphatasia - Epidemiology Forecast-2034" report has been added to ResearchAndMarkets.com's offering. The "Hypophosphatasia - Epidemiology...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
December 16, 2024 06:05 ET
|
MannKind
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 12, 2024 17:02 ET
|
Biomea Fusion, Inc.
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels...
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
December 11, 2024 06:00 ET
|
MannKind
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
India Diabetes Care Market Report 2024: Focus on Digital Health Solutions and Telemedicine, Personalized Medicine and Data Analytics
December 11, 2024 04:11 ET
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "India Diabetes Care Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...